R3 Medical Companies: FDA Warning Letter, Aug 14, 2026
Status: Unknown as of Oct 16, 2026. Warning letters are informal and advisory, not final agency action. Original on FDA.gov.
- Company
- R3 Medical Companies (as published by FDA)
- Letter date
- Aug 14, 2026
- Posted
- Aug 25, 2026
- Office
- Center for Biologics Evaluation and Research (CBER)
- Subject
- “Unapproved New Drugs/Unlicensed Biological Product Violations”
- Response
- None posted by FDA as of last check
- Close-out
- None posted by FDA as of last check
- Source
- FDA.gov · retrieved Oct 16, 2026
Get new FDA warning letters by email. One digest a week, free.
Double opt-in: we email you a link to confirm. One-click unsubscribe in every email. You must be at least 18. See our Privacy policy.
Need it same day for your suppliers? Reserve a founding Pro seat.
Text above is quoted or paraphrased from FDA.
Something wrong or out of date? Request a correction. We review correction requests within 5 business days.